You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
|
|---|---|
| Published in |
Frontiers in oncology, September 2018
|
| DOI | 10.3389/fonc.2018.00351 |
| Pubmed ID | |
| Authors |
Jun Zhang, L. Jeffrey Medeiros, Ken H. Young |
| Abstract |
Remarkable progress has been made in the field of cancer immunotherapy in the past few years. Immunotherapy has become a standard treatment option for patients with various cancers, including melanoma, lymphoma, and carcinomas of the lungs, kidneys, bladder, and head and neck. Promising immunotherapy approaches, such as chimeric antigen receptor (CAR) T cell therapy and therapeutic blockade of immune checkpoints, in particular cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 pathway (PD-1/PD-L1), have boosted the development of new therapeutic regimens for patients with cancer. Immunotherapeutic strategies for diffuse large B-cell lymphoma (DLBCL) include monoclonal anti-CD20 antibody (rituximab), monoclonal anti-PD-1 antibodies (nivolumab and pembrolizumab), monoclonal anti-PD-L1 antibodies (avelumab, durvalumab, and atezolizumab) and chimeric antigen receptor (CAR) T cell therapy. In this review, we outline the latest highlights and progress in using immunotherapy to treat patients with DLBCL, with a focus on the therapeutic blockade of PD-1/PD-L1 and CAR T cell therapy in DLBCL. We also discuss current clinical trials of PD-1/PD-L1 and CAR T cell therapy and review the challenges and opportunities of using immunotherapy for the treatment of DLBCL. |
X Demographics
The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 25% |
| Chile | 1 | 13% |
| Venezuela, Bolivarian Republic of | 1 | 13% |
| Spain | 1 | 13% |
| United Kingdom | 1 | 13% |
| Switzerland | 1 | 13% |
| Unknown | 1 | 13% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 88% |
| Practitioners (doctors, other healthcare professionals) | 1 | 13% |
Mendeley readers
The data shown below were compiled from readership statistics for 156 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 156 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 28 | 18% |
| Student > Bachelor | 17 | 11% |
| Student > Master | 15 | 10% |
| Other | 13 | 8% |
| Student > Ph. D. Student | 10 | 6% |
| Other | 24 | 15% |
| Unknown | 49 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 26% |
| Biochemistry, Genetics and Molecular Biology | 30 | 19% |
| Pharmacology, Toxicology and Pharmaceutical Science | 10 | 6% |
| Agricultural and Biological Sciences | 9 | 6% |
| Immunology and Microbiology | 6 | 4% |
| Other | 9 | 6% |
| Unknown | 52 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 April 2020.
All research outputs
#4,920,347
of 26,009,886 outputs
Outputs from Frontiers in oncology
#1,711
of 22,870 outputs
Outputs of similar age
#87,561
of 350,576 outputs
Outputs of similar age from Frontiers in oncology
#33
of 187 outputs
Altmetric has tracked 26,009,886 research outputs across all sources so far. Compared to these this one has done well and is in the 80th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 22,870 research outputs from this source. They receive a mean Attention Score of 3.1. This one has done particularly well, scoring higher than 92% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 350,576 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 187 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.